Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G0VV
|
|||
| Former ID |
DNCL002112
|
|||
| Drug Name |
Bafetinib
|
|||
| Synonyms |
Bafetinib; 859212-16-1; INNO-406; NS-187; UNII-NVW4Z03I9B; CNS-9; NVW4Z03I9B; INNO406; CHEMBL206834; (S)-N-(3-([4,5'-bipyrimidin]-2-ylamino)-4-methylphenyl)-4-((3-(dimethylamino)pyrrolidin-1-yl)methyl)-3-(trifluoromethyl)benzamide; 4-[[(3S)-3-DIMETHYLAMINOPYRROLIDIN-1-YL]METHYL]-N-[4-METHYL-3-[(4-PYRIMIDIN-5-YLPYRIMIDIN-2-YL)AMINO]PHENYL]-3-(TRIFLUOROMETHYL)BENZAMIDE; INNO 406; NS 187; N-[3-(4,5'-Bipyrimidin-2-Ylamino)-4-Methylphenyl]-4-{[(3s)-3-(Dimethylamino)pyrrolidin-1-Yl]methyl}-3-(Trifluoromethyl)benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bone disease [ICD-11: FC0Z; ICD-10: XIII; ICD-9: 185] | Phase 2 | [1], [2] | |
| Company |
CytRx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C30H31F3N8O
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)NC(=O)C2=CC(=C(C=C2)CN3CCC(C3)N(C)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CN=C5
|
|||
| InChI |
1S/C30H31F3N8O/c1-19-4-7-23(13-27(19)39-29-36-10-8-26(38-29)22-14-34-18-35-15-22)37-28(42)20-5-6-21(25(12-20)30(31,32)33)16-41-11-9-24(17-41)40(2)3/h4-8,10,12-15,18,24H,9,11,16-17H2,1-3H3,(H,37,42)(H,36,38,39)/t24-/m0/s1
|
|||
| InChIKey |
ZGBAJMQHJDFTQJ-DEOSSOPVSA-N
|
|||
| CAS Number |
CAS 859212-16-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16481656, 23539877, 24770036, 42466793, 50086918, 77698388, 103482046, 104063920, 126679896, 136340257, 137150513, 140810745, 141894470, 163312234, 164043536, 164836111, 172914862, 174531022, 180190671, 198990636, 223683336, 228773215, 244669216, 249565589, 249582875, 252160748, 252214950, 252543450
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7906). | |||
| REF 2 | ClinicalTrials.gov (NCT01215799) Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.